Q

Quest Diagnostics

Operates nationwide clinical laboratory testing

Senior Lab Robotics Automation Engineer

Full-Time
No salary listed
Mid, Senior
Bachelor's, Master's, PhD
Lewisville, TX, USA
In Person
Electrical EngineeringControls & Automation Engineering

About the job

Requirements
  • Minimum of 3–6 years of experience with laboratory automation and robotics; the required experience threshold is 3 years with a Ph.D., at least 4 years with a Master's degree, or at least 6 years with a Bachelor's degree, typically acquired in an academic or industrial setting.
  • Knowledge of laboratory operations.
  • Ability to work with and coordinate vendors and contracts.
  • Strong computer skills with programming languages such as Python, C++, Java, and C#.
  • Ability to work in a fast-paced, multitasking environment while maintaining department production and quality standards.
  • Ability to handle or feel objects, tools, and controls; reach with hands and arms to operate equipment or instruments; sit and stand frequently; and walk and stoop occasionally.
  • Ability to frequently lift or move up to 10 pounds and occasionally lift or move up to 25 pounds.
  • Close vision and depth perception.
  • Ability to work in a laboratory environment using standard lab equipment and personal protective equipment, follow safe chemical-handling procedures, and comply with Environmental Health & Safety policies and procedures in a biohazard environment.
  • Ability to travel up to 5%.
Responsibilities
  • Use automated systems software to program and schedule methods, teach labware positions, create custom liquid classes, and test relevant laboratory robotics and automation, including systems from Tecan, Hamilton, and Agilent.
  • Design automated workflow protocols, code custom scripts, define teach-point verification strategies, draft instrument performance qualification and maintenance documentation, and train operational staff to use related systems properly.
  • Collaborate with development and bioinformatics teams to build and test requirements for a Laboratory Information Management System (LIMS) interface with automated workflows.
  • Collaborate with laboratory personnel to define instrument user-interface and user-experience (UI/UX) requirements.
  • Develop, plan, and conduct complex experiments within a specific product or technology area while following defined protocols and company procedures.
  • Accurately record and report experimental results; prepare detailed documentation; summarize findings; interpret outcomes; and recommend alternative experiments when needed.
  • Work on individual assignments and longer-term project teams within established parameters; present, report, and provide updates to the supervisor or project team; and contribute ideas to improve team processes.
  • Participate in technical decisions affecting product development, identify problems, investigate alternatives, and recommend possible courses of action.
  • Work with team members and personnel from operations, product transfer, project management, and quality departments to meet department and project objectives.
  • Collaborate with manufacturer and vendor service representatives on instrument maintenance, repair, and installation, and participate as a technical resource in servicing and preventive maintenance of robotic instrumentation.
  • Train laboratory personnel in equipment operation, preventive maintenance, and repair techniques, including through travel to other sites when needed.
  • Work with the technical department to address and troubleshoot instrument issues or difficulties during downtime.
  • Attend specialized training programs as needed to stay current with instrumentation changes and establish proficiency with new technology.
  • Attend technical conferences or seminars and stay informed about technological developments through current literature; apply improved automated and scientific methods or technologies and contribute ideas for new product development in existing markets.
  • Collaborate with scientific staff and technical departments to evaluate equipment purchases and validate new assays on complex analytical instrumentation.
  • Liaise with R&D, Operations, and department managers to coordinate implementation of new tests and modifications.
  • Coordinate and plan instrument moves to designated spaces in collaboration with laboratory and facilities departments.
  • Independently manage time, projects, and assigned tasks, ensuring project goals and objectives are achieved within specified timeframes.
  • Ensure compliance with regulatory agency requirements through documentation, audits, and corrective action.
  • Perform other tasks as specified by the manager or director.
Desired Qualifications
  • At least 4 years of experience programming, developing, and testing robotics and automated instrumentation from manufacturers such as Hamilton, Tecan, or Agilent.
  • At least 3 years of experience with integrated robotic systems and related scheduling software, such as HighRes, Biosero, or custom solutions.
  • Service engineer experience with an instrument vendor.
  • Research experience in a clinical laboratory environment.

About the company

Quest Diagnostics provides clinical laboratory testing and diagnostic services. It processes patient samples across a network of laboratories to run a broad menu of 3,000+ tests, including cancer diagnostics and anatomical pathology, and delivers interpretive reports through its medical staff. Tests are performed at its patient service centers, esoteric and rapid-response labs, and outpatient facilities, with results shared with clinicians via connected data systems. What sets Quest Diagnostics apart is its scale and scope: the world’s largest clinical lab network, the broadest test menu, a large team of MDs and PhDs for interpretation, and leadership in cancer diagnostics and pre-employment drug testing, plus extensive clinical trials testing. Its goal is to empower healthcare providers and patients with actionable diagnostic insights to identify, treat, and manage disease, inspire healthy behaviors, and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Secaucus, New Jersey

Founded

1967

Get referred to Quest Diagnostics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apple Health users will order Quest tests later in 2026, expanding direct-to-consumer reach.
  • Quest’s consumer-health business reached $250 million in 2025 and management targets 30% 2026 growth.
  • Quest will launch Roche pTau217 and its new multi-biomarker AD-Detect panel in Q4 2026.

What critics are saying

  • CMS cuts lab reimbursement up to 15% on January 1, 2027, hitting CMS revenue.
  • Quest faces NLRB case 14-CA-378210 over alleged discharge and coercive statements in St. Louis.
  • Repeated PAMA cuts and commoditized testing can squeeze Quest into a low-margin processing utility.

What makes Quest Diagnostics unique

  • Quest serves half of U.S. physicians and hospitals through 2,000 service centers.
  • Quest built a consumer-health platform with Apple Health, Oura, Hims & Hers, and Function Health.
  • Quest leads blood-based Alzheimer’s diagnostics with AD-Detect and Roche pTau217 launches in 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Performance Bonus
  • Employee Stock Purchase Plan
  • Tuition Reimbursement
  • Wellness Program
  • Paid Vacation
  • Paid Holidays
  • Flexible Work Hours
  • 401(k) Retirement Plan

Company News

Yahoo Finance
Sep 22nd, 2026
Quest Diagnostics drops 5% as US cuts lab test reimbursement rates by 15%

Quest Diagnostics stock fell 5.1% on Tuesday after the Centers for Medicare and Medicaid Services announced it would cut reimbursement rates for lab work by up to 15%, effective 1 January 2027. CMS disclosed it has been paying approximately 16% more for lab tests than private insurers. The rate cuts could save taxpayers $1 billion annually but will reduce Quest's revenue. The company derives about 11% of its revenue from CMS reimbursement. If rates decrease by the full 15%, Quest's annual revenue would drop by 1.65%. Successive 15% annual reductions are possible through 2029, meaning a worst-case revenue reduction of slightly less than 5%. The company had warned in its SEC filing that Medicare and Medicaid rate changes posed risks to its business.

Citybiz
Sep 14th, 2026
Quanterix names yuri Fesko chief medical officer as diagnostics business expands.

Quanterix names yuri Fesko chief medical officer as diagnostics business expands. September 14, 2026 Dr. Yuri Fesko Quanterix Corporation has appointed Dr. Yuri Fesko chief medical officer, adding an experienced diagnostics executive as the company prepares for a broader market launch of its Lucent AD(R) Complete Alzheimer's disease test and advances regulatory work for its HD-X instrument. Fesko will provide medical and clinical leadership across the Nasdaq-listed precision biomarker company, working with its Diagnostics, Scientific, R&D, Regulatory and Commercial teams. He will be based at Quanterix's headquarters in Billerica, Massachusetts. The newly created role comes as Quanterix works to expand its diagnostics business and move more of its biomarker technologies into clinical applications. President and CEO Everett Cunningham said Fesko's background in clinical affairs and precision medicine will support both the commercialization of Lucent AD Complete and the company's planned IVD filing for HD-X. "As we prepare for the broader market launch of our Lucent AD Complete five biomarker test for Alzheimer's Disease, we welcome Dr. Yuri Fesko to Quanterix in an important new role to support our efforts to efficiently scale our expansion in diagnostics," Cunningham said. Fesko most recently served as chief medical officer at Quest Diagnostics, where he oversaw Medical Affairs, Clinical Development, Analytics and Public Health. He also served as the medical lead supporting the company's Quality and Regulatory functions and provided senior medical leadership for pathology and dermatopathology. His experience spans the development and implementation of precision medicine strategies in oncology, metabolic disease, neurology and consumer health. He has worked with health systems, pharmaceutical and biotechnology companies, and physician organizations to integrate precision diagnostics into clinical practice and clinical trials. Fesko also brings experience supporting FDA submissions, clinical development programs, companion diagnostic strategies and reimbursement planning. Those capabilities are relevant as Quanterix works to translate its biomarker research technologies into regulated diagnostic products and expand their use in clinical settings. One immediate priority is Lucent AD Complete, Quanterix's five-biomarker blood test for Alzheimer's disease. The company is preparing for a broader market launch of the test while simultaneously advancing the IVD regulatory filing for its HD-X instrument, making medical, regulatory and commercialization coordination a central part of Fesko's mandate. Cunningham said Fesko's ability to work across medicine, diagnostics, analytics and business strategy will support the company's efforts to build its Diagnostics business and broaden the clinical applications of its technology. Quanterix develops precision biomarker technologies designed to detect and quantify biological markers at very low concentrations. Its Simoa(R) platform provides high-sensitivity biomarker measurement in blood and other fluids, supporting applications across disease research, diagnostics and drug development. The company's technology portfolio has also expanded through its acquisition of Akoya Biosciences. Quanterix Spatial solutions provide high-plex quantitative protein analysis in tissue at single-cell resolution, adding spatial biology capabilities alongside its existing fluid biomarker technologies. Quanterix also operates Accelerator Laboratory services, providing researchers with additional capabilities for moving biomarker discoveries toward diagnostic applications. Together, those businesses give the company a platform spanning biomarker measurement, spatial analysis and laboratory services as it increases its focus on precision diagnostics. Fesko earned both his bachelor's degree and Doctor of Medicine from Case Western Reserve University and completed a fellowship at University Hospitals of Cleveland. He is board-certified in internal medicine, hematology and medical oncology. His appointment adds senior clinical leadership at a point when Quanterix is managing both product commercialization and regulatory execution. As the company expands beyond research applications, Fesko will help coordinate the medical evidence, regulatory strategy and clinical adoption required to move its biomarker technologies more broadly into diagnostic workflows.

PR Newswire
Sep 9th, 2026
Apple Health app users to order lab tests from Quest Diagnostics for $119

Apple Health app users in the United States will be able to purchase laboratory tests from Quest Diagnostics directly through the app later this year. Apple announced the update at its September event. Users can buy a Quest laboratory panel featuring over 50 biomarkers for $119. The panel assesses cardiometabolic health and organ function, including biometric readings for blood pressure, height, weight, and waist and hip circumferences. Customers can schedule blood draws and biometric readings at approximately 2,000 Quest patient service centres across the US. Results will appear in the Apple Health app shortly after testing. Quest collaborates with third-party providers to review test orders and discuss results at no additional charge.

Yahoo Finance
Sep 8th, 2026
Quest Diagnostics CEO sells 10,000 shares for $2.4M under pre-arranged trading plan

J.E. Davis, CEO and President of Quest Diagnostics, sold 10,000 shares of the diagnostic testing company for $2.4 million on 1 September 2026, according to an SEC Form 4 filing. The shares were sold at $242.72 each under a Rule 10b5-1 trading plan. Following the transaction, Davis retains 122,423 shares in the company, valued at $28.9 million. The sale occurred after Quest Diagnostics shares delivered a 32% total return over the preceding 12 months. Quest Diagnostics reported revenue of $11.6 billion and net income of $1.1 billion over the trailing twelve months. The company has a market capitalisation of $26.4 billion.

Ticker Report
Sep 5th, 2026
Man Group plc Makes New $495,000 Investment in Quest Diagnostics Incorporated $DGX

Man Group plc purchased a new position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,336 shares of the medical research company’s stock, valued at approximately $495,000. Several other hedge funds […]